SG10201911221RA - Bicyclic heteroaryl derivatives as cftr potentiators - Google Patents
Bicyclic heteroaryl derivatives as cftr potentiatorsInfo
- Publication number
- SG10201911221RA SG10201911221RA SG10201911221RA SG10201911221RA SG10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA
- Authority
- SG
- Singapore
- Prior art keywords
- bicyclic heteroaryl
- heteroaryl derivatives
- cftr potentiators
- potentiators
- cftr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435253P | 2016-12-16 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911221RA true SG10201911221RA (en) | 2020-02-27 |
Family
ID=62557188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911221RA SG10201911221RA (en) | 2016-12-16 | 2017-12-14 | Bicyclic heteroaryl derivatives as cftr potentiators |
| SG10201911076QA SG10201911076QA (en) | 2016-12-16 | 2017-12-14 | Bycyclic heteroaryl derivatives as cftr potentiators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911076QA SG10201911076QA (en) | 2016-12-16 | 2017-12-14 | Bycyclic heteroaryl derivatives as cftr potentiators |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10131670B2 (enExample) |
| EP (1) | EP3554506B1 (enExample) |
| JP (1) | JP7150721B2 (enExample) |
| CN (1) | CN110300589B (enExample) |
| AU (2) | AU2017378324B2 (enExample) |
| CA (1) | CA3046968A1 (enExample) |
| MX (1) | MX391651B (enExample) |
| RU (1) | RU2753056C2 (enExample) |
| SG (2) | SG10201911221RA (enExample) |
| WO (1) | WO2018112149A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015328174B2 (en) | 2014-10-06 | 2020-05-21 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EA201890913A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | Пиразоловые соединения в качестве ингибиторов акк и их применение |
| BR112018010453B1 (pt) | 2015-11-25 | 2022-06-14 | Gilead Apollo, Llc | Compostos triazólicos inibindores de acetil coa carboxilase (acc) |
| EP3380478B1 (en) | 2015-11-25 | 2020-12-23 | Gilead Apollo, LLC | Ester acc inhibitors and uses thereof |
| KR20180086191A (ko) | 2015-11-25 | 2018-07-30 | 길리어드 아폴로, 엘엘씨 | 2,4-디옥소-1,4-디히드로티에노[2,3-d]피리미딘 유도체를 함유하는 살진균 조성물 |
| JOP20190042B1 (ar) | 2016-09-30 | 2021-08-17 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
| JOP20190125B1 (ar) | 2016-12-09 | 2022-03-14 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
| EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| CA3085006A1 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| JOP20200178A1 (ar) | 2018-02-15 | 2022-10-30 | Vertex Pharma | حلقات ضخمة كمعدلات لمنظم توصيل التليف الكيسي عبر الغشاء، وتركيبات صيدلانية منها، واستخدامها في علاج التليف الكيسي، وعملية لتصنيعها |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| MX2021015133A (es) * | 2019-06-10 | 2022-01-24 | Novartis Ag | Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia. |
| MX2022000549A (es) | 2019-07-15 | 2022-02-10 | Novartis Ag | Formulaciones de (s)-3-amino-6-metoxi-n-(3,3,3-trifluoro-2-hidroxi -2-metilpropil)-5-(trifluorometil)picolinamida. |
| CA3150736A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Process of making cftr modulators |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| JP2023538125A (ja) | 2020-08-20 | 2023-09-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 粘液過剰分泌を特徴とする呼吸器疾患を処置するための方法 |
| IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
| CN112876524B (zh) * | 2021-01-26 | 2022-10-28 | 上海法默生物科技有限公司 | 一种瑞德西韦中间体的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| BRPI0619146A2 (pt) | 2005-12-02 | 2011-09-13 | Bayer Pharmaceuticals Corp | derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis |
| CA2635231C (en) * | 2005-12-29 | 2014-07-15 | Abbott Laboratories | Protein kinase inhibitors |
| CA2909277A1 (en) * | 2006-04-04 | 2007-10-11 | Kevan M. Shokat | Kinase antagonists |
| EP2217239A2 (en) * | 2007-11-07 | 2010-08-18 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| SI2531187T1 (sl) * | 2010-02-05 | 2016-01-29 | Adverio Pharma Gmbh | Stimulatorji sGC ali aktivatorji sGC sami in v kombinaciji z inhibitorji PDE5 za zdravljenje cistične fibroze |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| JP6371838B2 (ja) * | 2013-07-02 | 2018-08-08 | ライゼン・ファーマシューティカルズ・エスアー | Ｐｉ３ｋタンパク質キナーゼ阻害剤、特に、デルタ及び／またはガンマ阻害剤 |
| US10301315B2 (en) * | 2016-11-18 | 2019-05-28 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrrolopyrimidines as CFTR potentiators |
-
2017
- 2017-12-14 US US15/841,902 patent/US10131670B2/en active Active
- 2017-12-14 CN CN201780086700.9A patent/CN110300589B/zh active Active
- 2017-12-14 CA CA3046968A patent/CA3046968A1/en active Pending
- 2017-12-14 SG SG10201911221RA patent/SG10201911221RA/en unknown
- 2017-12-14 EP EP17879832.8A patent/EP3554506B1/en active Active
- 2017-12-14 MX MX2019007135A patent/MX391651B/es unknown
- 2017-12-14 RU RU2019120990A patent/RU2753056C2/ru active
- 2017-12-14 WO PCT/US2017/066317 patent/WO2018112149A1/en not_active Ceased
- 2017-12-14 AU AU2017378324A patent/AU2017378324B2/en active Active
- 2017-12-14 SG SG10201911076QA patent/SG10201911076QA/en unknown
- 2017-12-14 JP JP2019531417A patent/JP7150721B2/ja active Active
-
2018
- 2018-09-17 US US16/132,894 patent/US10208053B2/en active Active
- 2018-09-17 US US16/132,960 patent/US10377762B2/en active Active
-
2019
- 2019-07-09 US US16/506,883 patent/US10766904B2/en active Active
-
2021
- 2021-12-02 AU AU2021277702A patent/AU2021277702B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017378324A1 (en) | 2019-06-27 |
| AU2017378324B2 (en) | 2021-09-02 |
| WO2018112149A1 (en) | 2018-06-21 |
| EP3554506A4 (en) | 2020-06-10 |
| CN110300589B (zh) | 2023-03-10 |
| US10766904B2 (en) | 2020-09-08 |
| EP3554506B1 (en) | 2021-04-28 |
| US20180170938A1 (en) | 2018-06-21 |
| US10377762B2 (en) | 2019-08-13 |
| SG10201911076QA (en) | 2020-01-30 |
| US20190016728A1 (en) | 2019-01-17 |
| MX391651B (es) | 2025-03-21 |
| US10131670B2 (en) | 2018-11-20 |
| RU2019120990A3 (enExample) | 2021-01-18 |
| US20190330219A1 (en) | 2019-10-31 |
| JP7150721B2 (ja) | 2022-10-11 |
| EP3554506A1 (en) | 2019-10-23 |
| MX2019007135A (es) | 2019-11-18 |
| US20190016727A1 (en) | 2019-01-17 |
| CN110300589A (zh) | 2019-10-01 |
| AU2021277702B2 (en) | 2023-11-30 |
| AU2021277702A1 (en) | 2021-12-23 |
| RU2019120990A (ru) | 2021-01-18 |
| US10208053B2 (en) | 2019-02-19 |
| CA3046968A1 (en) | 2018-06-21 |
| RU2753056C2 (ru) | 2021-08-11 |
| JP2020502103A (ja) | 2020-01-23 |
| BR112019012335A2 (pt) | 2020-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201911221RA (en) | Bicyclic heteroaryl derivatives as cftr potentiators | |
| IL266668A (en) | Pyrrolopyrimidines as cftr enhancers | |
| IL256808A (en) | Heteroaryl derivatives as parp inhibitors | |
| IL246474A0 (en) | Heteroaryl substituted nicotinamide compounds | |
| ZA201606942B (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| EP3116858A4 (en) | Azaspiro derivatives as trpm8 antagonists | |
| IL253588A0 (en) | History of bicyclic quinazolinones | |
| EP3284637A4 (en) | Curtain airbag | |
| EP3352758A4 (en) | Deuterated cftr potentiators | |
| EP3253753A4 (en) | Ergoline compounds and uses thereof | |
| SG11201805869XA (en) | Quinolin-2-one derivatives | |
| EP3323809A4 (en) | Bicyclic heterocyclic amide derivative | |
| ZA201804966B (en) | 2-oxindole compounds | |
| EP3294737A4 (en) | Bicyclic compounds | |
| EP3225618A4 (en) | Bicyclic compound | |
| EP3181554A4 (en) | Quinazoline derivative | |
| EP3434149A4 (en) | CHILD BED THAT CAN BE REASSEMBLED | |
| EP3101004A4 (en) | Bipyridyl compound | |
| HUP1600234A2 (en) | Mdr-reversing 8-hydroxy-quinoline derivatives | |
| EP3269721A4 (en) | Bicyclic pyridine compound | |
| SG11202102137SA (en) | Bicyclic heteroaryl derivatives | |
| EP3150598A4 (en) | Substituted tropane derivatives | |
| PT3319956T (pt) | Derivados de oxopiridina substituída | |
| HK1230588A1 (en) | Heteroaryl substituted nicotinamide compounds | |
| AU2015902298A0 (en) | Anti-fungal potentiators |